IMO-3100: Phase I data

A placebo-controlled, multiple-dose Phase I trial in 24 healthy volunteers showed that once-weekly 0.64 mg/kg and twice-weekly 0.32 mg/kg subcutaneous IMO-3100 for 4 weeks were well tolerated with no ...